SeaStar Medical and LMF Published Results of Selective Cytopheretic Device in (Pilot SCD 005) Study for COVID-19 in SCCM 2022, Critical Care Explorations
- The (pilot SCD 005) study evaluate SCD (extracorporeal immunomodulator) in 22 patients with COVID-19 patients with multiple organ failures in ICU
- The study met its 1EPs i.e., reductions in activated neutrophils & monocytes that led to a reduction in proinflammatory cytokines & improved clinical outcomes, reduction in 60-day mortality in ICU patients (50% vs 81% in the control cohort), patients had a reduction in mortality to 31% @≥96hrs. of SCD treatment & showed an acceptable safety profile with no device-related SAEs
- The SCD was integrated into the CRRT blood circuit with low ionized calcium concentrations of 0.25 to 0.4 mmol/L were maintained using regional citrate anticoagulation & calcium-free dialysate
Ref: Globe Newswire | Image: Seastar
Click here to read the full press release
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at [email protected].